Fluorodeoxyglucose-PET in the management of malignant melanoma
- 1 January 2005
- journal article
- review article
- Published by Elsevier in Radiologic Clinics of North America
- Vol. 43 (1), 23-33
- https://doi.org/10.1016/j.rcl.2004.09.011
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Five years of sentinel node biopsy for melanoma: the St George's Melanoma Unit experienceBritish Journal of Plastic Surgery, 2004
- Computerised tomography in the staging of Hodgkin's disease and non-Hodgkin's lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Metastatic pathways and time courses in the orderly progression of cutaneous melanomaBritish Journal of Dermatology, 2002
- Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging SystemJournal of Clinical Oncology, 2001
- Comparison of Positron Emission Tomography Scanning and Sentinel Node Biopsy in the Detection of Micrometastases of Primary Cutaneous Malignant MelanomaJournal of Clinical Oncology, 2001
- Prospective Study of Fluorodeoxyglucose–Positron Emission Tomography Imaging of Lymph Node Basins in Melanoma Patients Undergoing Sentinel Node BiopsyJournal of Clinical Oncology, 1999
- Multi-Institutional Melanoma Lymphatic Mapping Experience: The Prognostic Value of Sentinel Lymph Node Status in 612 Stage I or II Melanoma PatientsJournal of Clinical Oncology, 1999
- Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma.Journal of Clinical Oncology, 1998
- Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanomaJournal of Surgical Oncology, 1997
- Positron Emission Tomography and UltrasonographyArchives of Dermatology, 1995